A Two Part Seamless, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7034067 in Infants With Type 1 Spinal Muscular Atrophy
Phase of Trial: Phase II/III
Latest Information Update: 12 Apr 2018
At a glance
- Drugs RG 7916 (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; Therapeutic Use
- Acronyms FIREFISH
- Sponsors Chugai Pharmaceutical; Roche
- 15 Mar 2018 According to a PTC Therapeutics media release, first patient has been dosed in the pivotal phase of this trial.
- 27 Feb 2018 Planned End Date changed from 1 Jan 2021 to 2 Sep 2020.
- 27 Feb 2018 Planned primary completion date changed from 30 Nov 2020 to 2 Sep 2020.